Seribantumab
- CAS No.
- 1334296-12-6
- Chemical Name:
- Seribantumab
- Synonyms
- Seribantumab;Seribantumab (anti-ERBB3);Research Grade Seribantumab;Research Grade Seribantumab(DHD48405)
- CBNumber:
- CB78080876
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 1N3L70MDFX |
| NCI Drug Dictionary | seribantumab |
Seribantumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0620926 | Seribantumab 96.043% | 1334296-12-6 | 1mg | $130 | 2026-06-04 | Buy |
| ChemScene | CS-0620926 | Seribantumab 96.043% | 1334296-12-6 | 5mg | $390 | 2026-06-04 | Buy |
| ChemScene | CS-0620926 | Seribantumab 96.043% | 1334296-12-6 | 10mg | $628 | 2026-06-04 | Buy |
| aablocks | AA0294TP | Seribantumab ≥95%(SDS-PAGE&SEC-HPLC) | 1334296-12-6 | 1mg | $183 | 2026-06-02 | Buy |
| aablocks | AA0294TP | Seribantumab ≥95%(SDS-PAGE&SEC-HPLC) | 1334296-12-6 | 5mg | $856 | 2026-06-02 | Buy |
Seribantumab Chemical Properties,Uses,Production
Uses
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models[1].
in vivo
Seribantumab (0.6-1 mg; i.p. twice weekly for once) reduces tumor growth in non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) mice model with a higher efficacy than afatinib, blocks phosphorylation of growth modulators and induces expression of apoptosis markers in vivo[1]. Seribantumab (1-10 mg; i.p. twice weekly for once) eliminates the vast majority of tumor cells and causes no significant change in overall animal health or weight in High-grade serous ovarian cancer (HGSOC) mice model[1].
| Animal Model: | Immunocompromised mice with LUAD-0061AS3 PDX tumors implanted[1] |
| Dosage: | 0.6, 0.75 and 1 mg |
| Administration: | Intraperitoneal injection; 0.6, 0.75 and 1 mg for once |
| Result: | Effectively reduced tumor growth of mice and time- and dose-dependently reduced phosphorylation of HER2, HER3, AKT, and ERK1/2. Induced the expression if proapoptotic protein, BIM. |
References
[1] Odintsov I, et al. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clin Cancer Res. 2021 Jun 1;27(11):3154-3166. DOI:10.1158/1078-0432.CCR-20-3605
Seribantumab Preparation Products And Raw materials
Raw materials
Preparation Products
Seribantumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
View Lastest Price from Seribantumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Seribantumab
1334296-12-6
|
$78.00-237.00 | 96.26% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Seribantumab
1334296-12-6
- $78.00-237.00
- 96.26% (SEC-HPLC)
- TargetMol Chemicals Inc.
